Risk Mitigation. Upon execution of the Development Supply Agreement, with input and advice from Regeneron, Kiniksa shall develop a risk mitigation plan and supply chain strategy intended to ensure continuous uninterrupted supply of Product. With input and advice from Regeneron, Kiniksa shall update such plan upon execution of the Commercial Supply Agreement, and from time-to-time as may be necessary during the Term. In addition, at all times during the Term, Regeneron will ensure that it maintains supplies of raw materials sufficient to Manufacture quantities of the Product in accordance with any firm order requirements of Kiniksa in the Supply Agreements.
Appears in 2 contracts
Sources: License Agreement (Kiniksa Pharmaceuticals, Ltd.), License Agreement (Kiniksa Pharmaceuticals, Ltd.)